Corrigendum to "Effects of Oleuropein on tumor cell growth and bone remodeling: Potential clinical implications for the prevention and treatment of malignant bone diseases" [Life Sci. 264 (2021) 118694].

Autor: Leto G; Laboratory of Experimental Pharmacology, Department of Health Sciences, University of Palermo, 90127 Palermo, Italy. Electronic address: gaetano.leto@unipa.it., Flandina C; Laboratory of Experimental Pharmacology, Department of Health Sciences, University of Palermo, 90127 Palermo, Italy., Crescimanno M; Laboratory of Experimental Pharmacology, Department of Health Sciences, University of Palermo, 90127 Palermo, Italy., Giammanco M; Department of Surgical, Oncological and Oral Sciences University of Palermo, 90127 Palermo, Italy., Sepporta MV; Pediatric Unit, Department Women-Mother-Children, Pediatric Hematology-Oncology Research Laboratory, Lausanne University Hospital, Lausanne, Switzerland.

Publikováno v: Life sciences [Life Sci] 2021 Aug 15; Vol. 279, pp. 119591. Date of Electronic Publication: 2021 May 08.

Effects of oleuropein on tumor cell growth and bone remodelling: Potential clinical implications for the prevention and treatment of malignant bone diseases.

Autor: Leto G; Laboratory of Experimental Pharmacology, Department of Health Sciences, University of Palermo, 90127 Palermo, Italy. Electronic address: gaetano.leto@unipa.it., Flandina C; Laboratory of Experimental Pharmacology, Department of Health Sciences, University of Palermo, 90127 Palermo, Italy., Crescimanno M; Laboratory of Experimental Pharmacology, Department of Health Sciences, University of Palermo, 90127 Palermo, Italy., Giammanco M; Department of Surgical, Oncological and Oral Sciences, University of Palermo, 90127 Palermo, Italy., Sepporta MV; Pediatric Unit, Department Women-Mother-Children, Pediatric Hematology-Oncology Research Laboratory, Lausanne University Hospital, Lausanne, Switzerland.

Publikováno v: Life sciences [Life Sci] 2021 Jan 01; Vol. 264, pp. 118694. Date of Electronic Publication: 2020 Oct 30.

Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases

Autor: gaetano leto, Badalamenti, G., Arcara, C., Crescimanno, M., Flandina, C., Tumminello, F. M., Incorvaia, L., Gebbia, N., Fulfaro, F.

Publikováno v: Scopus-Elsevier

Background: The effects of the bisphosphonate derivative zoledronic acid (ZA) on the > circulating levels of matrix metalloproteinase-2 (MMP-2), matrix metallo-proteinases-9 > (MMP-9), cathepsin B (Cath B) and urokinase-type plasminogen activator (uP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1fe2686e37bd03fd98a336905ae52f3d
http://hdl.handle.net/10447/32459

Development and Partial Characterization of a Human T-Lymphoblastic Leukemic (CCRF-CEM) Cell Line Resistant to Etoposide. Analysis of Possible Circumventing Approaches

Autor: N D'Alessandro, A. Flugy, Flandina C, Nicolò Borsellino

Publikováno v: Journal of Chemotherapy. 8:465-471

We have selected an etoposide-resistant variant (CCRF-CEM/VP-16) of the human T-lymphoblastic CCRF-CEM leukemia for study. Resistance to the topoisomerase II (topo II) inhibitor was about 11-fold and stable. Other data revealed that the new cell line

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95b8ff6cd26b588716c30ac1d3d2a679
https://doi.org/10.1179/joc.1996.8.6.465

Diagnostic Utility of Canine C-Reactive Protein, Haptoglobin, and 25-Hydroxyvitamin-D in Dogs with Nasal Cavity Disease.

Autor: Rösch, Sarah¹ (AUTHOR) sarah.rosch@ugent.be, Woitas, Julia¹ (AUTHOR) sarah.rosch@ugent.be, Oechtering, Gerhard Ulrich¹ (AUTHOR)

Publikováno v: Animals (2076-2615). Oct2024, Vol. 14 Issue 19, p2908. 17p.